The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
anytime you pharmacologically increase HDL cholesterol by inhibiting C tap nothing good seems to happen right because you're actually impairing your entry raters release for transport right so it has to be with effect right that's what it has to be a functional a functional thing of the HDL probably or the lipoprotein particle size or something
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
if you produce lots of Apple A1 you produce lots of pre-beta HDL particles to small HDL particles and these particles suck cholesterol out of peripheral tissues
the reason for the lower LDL is that they are sweeped up by the liver so these ldls actually get 50 lower which is a huge drop because the liver upregulates and what can deliver a regulate their LDL receptors at the same time